Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

A Fresh Look at CAR T-Cell Therapy: Recent Advances, New Evidence, and Evolving Paradigms to Improve Patient Care
  • CME
  • MOC

Credits Available
Physicians: maximum of 1.75 AMA PRA Category 1 Credits
ABIM MOC: maximum of 1.75 Medical Knowledge MOC point(s)
Released: December 8, 2020 Expiration: December 7, 2021
Start Activity
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Bristol-Myers Squibb
Renier J. Brentjens, MD, PhD
Program Director
Frederick L. Locke, MD
Noopur Raje, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Review the biologic principles underlying CAR T-cell therapy, structure and function of the CAR, and the mechanism of action of CAR T-cells
  • Identify characteristics of patients who are appropriate for treatment with CAR T-cell therapy
  • Integrate into practice clinical trial data on CAR T-cell–based therapies for the treatment of patients with leukemia and lymphoma
  • Evaluate emerging clinical data and novel approaches to CAR T-cell therapy for patients with myeloma

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Renier J. Brentjens, MD, PhD

Associate Professor
Department of Medicine
Weill Medical College of Cornell University
Associate Professor
Department of Pharmacology
Weill Cornell Graduate School of Medical Sciences
Associate Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Renier J. Brentjens, MD, PhD, has disclosed that he has patents and receives grant support from Juno Therapeutics (a Bristol-Myers Squibb company) and is a consultant/advisor for Gracell Therapeutics.

Faculty

Frederick L. Locke, MD

Co-Leader, Moffitt Immuno-Oncology Program
Vice Chair and Associate Member
Department of Blood and Marrow Transplant and Cellular Immunotherapy
Research Director
Medical Director

Immune Cell Therapy Program
Blood and Marrow Transplant and Cellular Immunotherapy
Moffitt Cancer Center
Tampa, Florida

Frederick L. Locke, MD, has disclosed that he has received consulting fees from Cellular Biomedicine, funds for research support from Gilead Sciences/Kite, and has served on advisory boards for Allogene, Amgen, Calibr, Bristol-Myers Squibb/Celgene, GammaDelta Therapeutics, Gilead Sciences/Kite, Novartis, and WuGen.
Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Noopur Raje, MD, has disclosed that she has received funds for research support from Bluebird and consulting fees from Amgen, Bristol-Myers Squibb, Caribou, Celgene, Immuneel, Janssen, Karyopharm, and Takeda.

Staff

Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who treat and manage patients with leukemia, lymphoma, or myeloma who are candidates for CAR T-cell therapies.

Goal

The goal of this activity is to improve the knowledge, competence, and performance of physicians and other healthcare providers so they can confidently and competently integrate CAR T-cell therapy into their clinical practices.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this activity, which includes participation in the evaluation component, enables the participant to earn up to 1.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 08, 2020, through December 07, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

A Fresh Look at CAR T-Cell Therapy: Recent Advances, New Evidence, and Evolving Paradigms to Improve Patient Care
  • CME
  • MOC

Loading...
In this interactive on-demand Webcast, expert faculty members discuss how they currently use CAR T-cells to treat hematologic malignancies and provide a look ahead at new data and promising agents that may soon change practice.
Renier J. Brentjens, MD, PhD
Program Director
Frederick L. Locke, MD
Noopur Raje, MD
Physicians: maximum of 1.75 AMA PRA Category 1 Credits
ABIM MOC: maximum of 1.75 Medical Knowledge MOC point(s)
Released: December 8, 2020 Expiration: December 7, 2021

Related Content

On-demand Clinical Care Options (CCO) webcast with experts’ review of data informing optimal management of relapsed/refractory myeloma

Shaji K. Kumar, MD
Program Director
Suzanne Lentzsch, MD, PhD Saad Z. Usmani, MD, MBA, FACP
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: March 31, 2021 Expired: March 30, 2022

From Clinical Care Options (CCO), read an expert commentary on how to safely provide CAR T-cell therapy during the COVID-19 pandemic

person default Caron A. Jacobson, MD Released: March 31, 2021

Free video from Clinical Care Options (CCO) featuring expert discussion of the latest updates in CAR T-cell therapy for hematologic cancers

Renier J. Brentjens, MD, PhD
Program Director
Frederick L. Locke, MD Noopur Raje, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: March 29, 2021 Expired: March 28, 2022

From Clinical Care Options (CCO), a commentary from 3 myeloma experts on selecting treatment for relapsed/refractory disease

Shaji K. Kumar, MD
Program Director
Suzanne Lentzsch, MD, PhD Saad Z. Usmani, MD, MBA, FACP
Released: March 29, 2021
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Bristol-Myers Squibb

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue